Medicines
Building on our platform of niche specialist injectables we have further innovative products in the pipeline which will enhance our portfolio of generic anti-bacterial, antifungal and antiviral medicines. By concentrating in specialist areas we are investing in areas traditionally overlooked by large pharmaceutical producers since patient numbers are small. We are therefore ensuring a sustainable and affordable alternative for the NHS and to patients who will benefit from these treatments.
Our portfolio is to be further enhanced by products within the cardiovascular and central nervous system areas of medicine.
Innovation
Putting patients at the heart of our investment we strive to be at the forefront of the latest personalized patient drug delivery systems
Together with our associates Kensington Pharma is innovating in the field of Pharmionics in order to enhance the real world experiences of drug administration and ultimately lead to better health outcomes.
The way forward is to have patient centric product strategies which are customised to the patient and the care giver. This approach aims to optimise drug delivery, dose frequency and simplify drug administration. Kensington Pharma is focusing on developing optimal drug delivery systems with the aim of improving the pharmokinetic and pharmodynamic properties of the medicines in our portfolio in order to optimise the effectiveness for each patient.
